What Versican Plus DHPPi/L4 Treats: Main Uses and Benefits

Versican Plus DHPPi/L4's therapeutic area is the proactive defense against infection of dogs from six weeks of age. This product is commonly used to help protect against a wide array of severe, infectious conditions.

This product's primary use is proactive defense against infection against core viral conditions, including Canine Distemper Virus, Canine Parvovirus, and Infectious Canine Hepatitis (CAV-1). The proactive defense helps provide support in avoiding the most severe outcomes of these infections, which are conditions marked by heightened physiological stress, such as systemic imbalance and profound organ strain.

It is also commonly used to provide supportive defense against four key Leptospira serovars that may cause kidney and liver disease. This provides supportive benefit by contributing to a reduction in the risk of acute organ failure signs and may assist in limiting the spread of the bacteria, supporting a decrease in zoonotic risk.

“The primary benefit provided is support that helps ease the overall symptom burden by preventing the onset of acute, life-threatening manifestations.”

Quick Fact: Relief for Infectious Disease Consequences

This proactive approach contributes to improved comfort during periods of potential exposure and assists with maintaining functional stability by helping to limit the severe consequences of acute viral and bacterial diseases.

Regulatory References

1. European Medicines Agency's (EMA) Summary of Product Characteristics

Eligibility Map: Who can and cannot use Versican Plus DHPPi/L4

Eligibility scope

Age-related eligibility rules:

The minimum approved age for the initial vaccination course is 6 weeks for all components. Use is established for the general adult dog population.

Pregnancy and lactation eligibility status:

The safety of the product has not been investigated for use during the early stage of pregnancy or during lactation, resulting in a formal "not recommended" status for these two periods.

Connection to the overall eligibility profile:

The regulatory profile establishes the eligible population as healthy dogs from 6 weeks of age. While no absolute contraindications are listed, the label imposes conditional use restrictions concerning the animal’s current health status and specific reproductive stages where safety data has not been established. Use is otherwise permitted for the general target species population.

Interactions with other medicines and products

Regulatory documentation for Versican Plus DHPPi/L4, a multivalent veterinary vaccine, defines its interaction profile primarily through constraints related to physical compatibility and co-administration with other immunological products.

Official Interaction Constraints

Immunological Considerations

The official labeling notes a specific interaction related to passive immunity in young dogs:

• Maternally Derived Antibodies (MDA): The immunological response to the viral components (Distemper, Adenovirus, and Parvovirus) may be delayed in puppies due to the presence of high levels of maternally derived antibodies. This requires a professional adjustment to the vaccination schedule.

No official regulatory information is available concerning metabolic (e.g., CYP-mediated) or transporter-based interactions, or interactions with food, alcohol, or herbal products.

The Versican Plus DHPPi/L4 vaccine provides a wide array of viral and bacterial antigens to the host immune system. Upon parenteral administration, these antigens are captured and processed by specialized antigen-presenting cells (APCs), which act as the primary biological target for initiating the mechanism. The APCs then migrate to lymphoid tissues, facilitating the interaction type of antigen presentation to T-lymphocytes. This molecular event activates the adaptive immune pathway, specifically involving the differentiation of B-lymphocytes into plasma cells, which is a key intracellular process. This downstream cascade results in the synthesis and release of pathogen-specific neutralizing antibodies (humoral immunity). Concurrently, T-lymphocytes differentiate into memory cells, establishing a state of immunological memory as the resultant system-level physiological consequence.

Versican Plus DHPPi/L4 is intended for active immunisation of dogs from six weeks of age against several key canine diseases.

Administration and Preparation

This product is administered as a single 1 ml dose via subcutaneous injection (under the skin). The veterinary medicinal product is presented as a lyophilisate (freeze-dried component) and a suspension (liquid solvent) that must be aseptically reconstituted immediately prior to use. Once mixed, the reconstituted vaccine should appear pinkish or yellowish with slight opalescence. It is essential to shake the mixture well and administer the entire contents immediately.

Dosage Schedule

The standard primary course requires two doses. For the Distemper (CDV), Adenovirus (CAV), and Parvovirus (CPV) components, a single dose is generally administered every three years. However, due to shorter durations of immunity for the Parainfluenza and Leptospira components, annual revaccination with a suitable compatible vaccine containing these components, such as Versican Plus Pi/L4, is required.

Research evidence / Overview of studies for Versican Plus DHPPi/L4

Evidence for Active Immunisation Against Core Canine Viral Diseases

The primary research base for the viral components of this product (Canine Distemper Virus, Adenovirus, Parvovirus, and Parainfluenza) relies mainly on Controlled Virulent Challenge Trials. These are laboratory studies where healthy puppies are vaccinated and then monitored after intentional exposure to the live, targeted virus. This type of research setting examined outcomes related to physiological strain, such as mortality or severe clinical signs.

Research has explored patterns of measured antibody levels for the core components (Distemper, Adenovirus, Parvovirus) over extended periods. Studies examined patterns observed where antibody levels were tracked for at least three years following the initial vaccination course. For one of the viral components, the duration of antibody presence was primarily established by measuring the presence of antibodies (serology) over the three-year interval, rather than relying on a direct challenge at the three-year mark.

Evidence for Active Immunisation Against Leptospira Serovars

The research base for the L4 components (protecting against four Leptospira serovars) also relies primarily on Controlled Virulent Challenge Trials. These laboratory research scenarios were evaluated in healthy puppies to assess patterns of immune response against these bacterial pathogens. The outcomes evaluated included clinical signs (systemic illness), infection patterns, and urinary excretion (shedding of bacteria).

Controlled studies reported patterns observed related to clinical signs and measurements related to urinary excretion following exposure to the targeted Leptospira serovars. Immunogenicity testing reported how symptoms evolved in the observed populations and tracked the presence of measured antibody levels for all four bacterial components.

Duration of Immunity and Long-Term Follow-up

Research has explored the durability of the immune response across the different components of the vaccine. The evidence base tracks two distinct periods of sustained antibody presence. The core viral components (Distemper, Adenovirus, Parvovirus) was studied for patterns of antibody presence lasting at least three years.

However, the period of study for the Parainfluenza component and all four Leptospira bacterial components was tracked for at least one year. There is limited information for long-term outcomes beyond these established intervals.

Evidence in Specific Puppy Populations

Research specifically was studied for the use of this product in healthy puppies from six weeks of age. Sub-studies were applied in research contexts involving young puppies that still had Maternally Derived Antibodies (MDA), which are antibodies passed from the mother. Findings indicate that the immunological response may be delayed when high levels of maternally derived antibodies are present.

What is Still Uncertain About Versican Plus DHPPi/L4 Evidence

The evidence base for regulatory approval includes research that highlights what is known and what is still uncertain. Follow-up durations were limited for the Parainfluenza and Leptospira components. Long-term effects are not fully established beyond the one-year timeframe. Furthermore, the primary efficacy evidence stems from controlled laboratory challenge models, which, while highly standardized, do not fully replicate complex, long-term environmental factors.

Common questions about Versican Plus DHPPi/L4 (FAQ)

Q: What is the difference between Versican Plus DHPPi/L4 and other 5-in-1 type treatments?

Official documents describe Versican Plus DHPPi/L4 as a multivalent combination vaccine. This means its formulation contains multiple distinct components that are designed to stimulate an immune response against nine different targets simultaneously, which includes four viral diseases and four bacterial serovars.

Q: What does the 'L4' part of the name Versican Plus DHPPi/L4 mean?

The 'L4' in the name is a shorthand for the components that protect against leptospirosis, a bacterial disease. Specifically, it provides antigens for four distinct Leptospira serovars: Icterohaemorrhagiae, Canicola, Grippotyphosa, and Bratislava.

Q: Why do some people worry about allergic reactions to Versican Plus DHPPi/L4?

Concerns about allergic reactions stem from official safety data. Regulatory documents state that hypersensitivity reactions, such as anaphylaxis, are documented as rare side effects that may occur following administration. These events are generally uncommon but are the basis for patient and professional caution.

Q: What specific conditions make a dog ineligible for Versican Plus DHPPi/L4?

While the official regulatory label states 'none' under contraindications, use is not recommended for all animals. Official warnings advise against its use in animals that are not in good health or those with a compromised immune system, as a fully competent immune system is necessary to develop the intended protective response.

Q: Can older dogs still receive Versican Plus DHPPi/L4?

Yes, the product information indicates that it is for dogs starting from six weeks of age and for the general adult dog population. Regulatory documentation does not specify an upper age limit, meaning its use is generally permitted for the adult population, including older dogs.

Q: What is the intended purpose of the Parvovirus component in Versican Plus DHPPi/L4?

The intended purpose of the Parvovirus component (CPV-2b) is to establish active immunity against canine parvovirus disease. This is a core part of the overall strategy of prophylaxis (preventative defense) provided by this combination product.

Q: Why is it important to know if a dog has had a prior reaction before using it again?

Because of the possibility of rare, but serious, adverse events such as hypersensitivity reactions, official documentation mentions the potential need for careful assessment due to the risk of rare, serious events. This requires the administering professional to be aware of the patient's prior reaction history before product use.

Q: What are the general expectations for the dog's behavior immediately after administration?

Most commonly reported effects are localized reactions at the injection site, such as transient swelling, pain, or warmth. Regulatory documents also note that rare adverse reactions include a temporary decreased activity (appearing tired) and anorexia (loss of appetite).

Q: Is the protection guaranteed for the full duration specified in studies?

Official documents describe the duration of immunity based on research evidence that tracks measured antibody levels in study populations. Like all medical products, official regulatory documents do not contain statements that guarantee complete or absolute protection from clinical disease.

Q: What are the common signs of an uncommon, severe reaction to look out for?

Rare, severe reactions may present as signs of a hypersensitivity reaction shortly after administration, such as facial swelling, severe itching, vomiting, or difficulty breathing. Official documents also note the very rare reports of immune-mediated disorders which may require medical attention.

Q: Does regulatory information clarify what type of protection the Leptospirosis part provides?

Studies supporting the L4 component focused on two main areas of protection. Research evidence primarily examined outcomes related to the prevention of clinical signs (systemic illness) and the prevention of urinary excretion (shedding of the bacteria).

Q: Why does Versican Plus DHPPi/L4 protect against so many diseases?

Official information defines the product as a multivalent combination vaccine. This structure allows it to target a wide spectrum of infectious diseases because its formulation contains multiple distinct antigens that stimulate the immune response against nine different pathogens simultaneously.

Q: Can Versican Plus DHPPi/L4 be used for all dog breeds?

According to the official product information, the product is indicated for the target species, Canidae (dogs). Regulatory documents do not specify any restrictions based on breed.

Q: Does this product protect against all types of Canine Influenza?

The 'Pi' component of the vaccine is intended to protect against Canine Parainfluenza Virus, which is a common respiratory pathogen. This is a different illness from Canine Influenza Virus, which is caused by a separate type of virus.

Q: What is the difference in components between the Plus DHPPi and the Plus DHPPi/L4 versions?

The primary difference is the Leptospira component. The DHPPi/L4 version contains the antigens for four specific Leptospira serovars (L4) in addition to the viral components, providing extended protection not present in the base DHPPi version.

Q: What does 'recombinant' mean in the context of this product's technology?

Regulatory documents state that one of the viral components, Canine Parvovirus (CPV-2b), is produced using recombinant technology. This means the antigen used to stimulate the immune system was created using controlled genetic engineering methods.

Q: What does the acronym 'DHPPi' stand for?

The 'DHPPi' acronym is a shorthand used to describe the viral components of the product. These components are intended to provide active immunisation against Distemper (D), Adenovirus (H), Parvovirus (P), and Parainfluenza (Pi).

Q: Can a dog experience mild fever after receiving Versican Plus DHPPi/L4?

While mild fever is not listed as a common expected reaction, official safety data notes that pyrexia (fever) has been associated with the very rare reports of immune-mediated disorders.

Q: Why do official materials emphasize the importance of using the full primary course?

Official documents emphasize the need for the full two-dose primary course in puppies. The second dose is necessary because it helps overcome a potential delay in immunological response caused by maternally derived antibodies (MDA) that puppies receive from their mother.

Q: What should be done if the product container appears damaged before administration?

The product must maintain its sterility and integrity up until the moment of use. If any damage is observed that might compromise the product's sterile condition, the product is generally required to be discarded according to local guidelines for medical waste disposal.

Q: What is the difference between immunity and protection as described in the official documents?

The official documentation uses the terms active immunisation and protection largely interchangeably. Both concepts describe the establishment of immunological memory within the body that is intended to resist or defend against clinical disease if exposure occurs.

Storage and Disposal Requirements

Official regulatory documentation dictates specific storage conditions to maintain the stability of Versican Plus DHPPi/L4. The product must be stored and transported refrigerated at a temperature between 2 C and 8 C at all times.

Disposal must adhere to specific pharmaceutical waste rules. The unused product or waste materials derived from its use should not be disposed of via wastewater or household waste. Disposal must occur through authorized take-back schemes in accordance with local and national requirements.